This Appendix describes methods and additional results for the TrialNet and European studies of the mixed meal tolerance test (MMTT) versus the Glucagon Stimulation Test (GST) to measure β-cell function in type 1 diabetes.
Methods
TrialNet Study. For the MMTT tests, participants were given 6 ml/kg of Boost up to maximum of 360 ml, to be ingested within 5 minutes. Samples were collected 10 minutes prior to the meal (-10) , at the time of ingestion (0), and at 15, 30, 60, 90 and 120 minutes thereafter. For the GST test, 1 mg of glucagon was injected intravenously within 10 seconds.
Samples were collected at -10, 0, 2, 4, 6, 8, and 10 minutes. Glucose, C-peptide, and HbA1c were measured at the TN β-cell function laboratory (Seattle, WA). Autoantibodies were measured at TN antibody laboratories (Gainesville, FL and Denver, CO).
C-peptide was measured using a two site immunoenzymometeric assay (1) performed on a Tosoh 600 II auto-analyzer (AIA-600 II Analyte Application Manual, Tosoh Bioscience, Inc. South San Francisco, CA). The upper limit of the analytical range of the assay is 30 ng/ml (9.9 pmol/ml). On May 16, 2005, the lower limit of quantification was lowered from 0.2 ng/ml to 0.04 ng/ml (0.066 to 0.013 pmol/ml). The inter-assay and intra-assay coefficients of variation were less than 10%.
European C-peptide Trial. MMTT and GST tests were conducted as described for the TN study with the exception that only one post-stimulus sample was obtained after glucagon injection (6 minutes).
Blood glucose measurements were performed by HEMOCUE-meters distributed from the central laboratory at Steno Diabetes Center, Copenhagen. C-peptide, blood glucose, hemoglobin A1c, and serum insulin (ELISA) were all measured in the central laboratory at the Steno Diabetes Center. The C-peptide in a sample was measured using a two-site fluoroimmunometric assay performed using an AutoDELFIA (Perkin Elmer-Wallac) Cpeptide kit. The analytical range of the assay is 0.01 -6.0 pmol/ml, 0.01 pmol/ml being the lower limit of quantification of the assay; the inter-assay coefficient of variation was less than 6%.
Statistical Methods. The area under the curve (AUC) was computed from all timed collections (including the basal) using the trapezoidal rule. The AUC mean equals the AUC divided by the interval of time, e.g. 120 minutes for a 2 hour MMTT. The AUC could not be computed for the European Study GST that only obtained a 6 minute value.
Analyses were conducted using the log transformation and the results presented as a geometric mean (exp(mean log(x)) and standard deviation factor (SDF = exp(SE of mean log(x)*square root (df))) from which the 95% confidence limits on the geometric mean were computed.
Bland-Altman plots (2) were used to assess homogeneity of error variation over the range of subject values. The ratio of the two values is plotted versus the geometric mean of the two for each subject.
There were no differences between the values of the first and second tests within subjects and thus values from all MMTTs and GSTs were employed with an adjustment for test order and other factors, and allowing for the inter-correlation among repeat measures in the same subject.
The differences in adverse reactions and preferences were compared across groups using the chi-squared test for independence, or Fisher's exact test, as appropriate. Table A1 presents the proportion of non-measurable C-peptide values below the lower limit of quantification of the assay. Figure A1 The European C-peptide values (panels C and D) appear to be lower than those in TrialNet (A and B). However, the distributions of values in the European study are similar to those in TrialNet when the analysis is restricted to the subjects with the same range of age and duration (panels E and F). Table A2 presents the inter-correlations among the various summary measures from the MMTT and GST within the TrialNet and European studies.
Results
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Summary Measures:
Separately for the TrialNet and European studies, Table A3 presents the distribution of the basal (fasting) values, the 90 minute MMTT and 6 minute GST values, the peak post-stimulus value and the AUC mean. For the European GST, the 6 minute value was used for the peak value. No AUC mean could be computed from the European GST. The quartiles are presented as well as the geometric mean and standard deviation factor (SDF) and the 95% confidence limits. In general, among the stimulated values, the MMTT values are higher than those from the GST.
Covariate Effects on C-peptide: Table A4 presents the effects of the log fasting Cpeptide, the fasting plasma glucose, age, sex and duration of diabetes on the MMTT and GST peak C-peptide in the TrialNet and European studies. Figure 2 of the main paper presents the scatter plots for the correlation of the AUC C-peptide from the replicate tests of the MMTT in the TrialNet and European studies, and of the AUC from the GST in TrialNet (not computed in the Eurpoean Study). Figure A2 presents Bland-Altman plots (2) that assess the assumption of homoscedasticity or the extent to which the random errors are scattered evenly over the range of the subject values. These showed that the variation within paired measurements was evenly distributed over the range of values for both MMTT and GST in both studies. * "Other" for TrialNet included excessive bleeding (1 for GST), vasovagal/fainting (2 GST, 3 MMTT), headache (14 GST, 4 MMTT), and various "other" conditions. "Other" for the European study was simply defined as "other". Figure A1 . Box plots showing the median (-), upper and lower quartiles, and the mean (•)C-peptide at each timed collection during the MMTT and the GST tests from TrialNet (Panels A and B) and the European Study (Panels C and D) using all measures in all subjects. Panels E and F present data from the European Study restricted to subjects with the same duration and age range as in TrialNet. 
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